My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Pfizer (NY:PFE)

23.89 -0.18 (-0.77%)

Streaming Delayed Price Updated: 11:43 AM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Pfizer vs Verizon Communications: Which High-Yielding Dividend Stock Is the Better Buy? ↗

Today 10:20 EDT

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Via The Motley Fool

Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest

June 30, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...

Via StockStory

Topics Artificial Intelligence Intellectual Property

The Fine Print Most Canadians Miss When Holding U.S. Stocks in a TFSA ↗

June 30, 2026

Maximize your investment opportunities in US stocks with a TFSA while being aware of the tax implications of dividends.

Via The Motley Fool

Topics Artificial Intelligence ETFs Retirement

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

June 30, 2026

Via Chartmill

Most active S&P500 stocks in Wednesday's session ↗

June 24, 2026

Via Chartmill

Why Pfizer Could Prove to Be an Underrated GLP-1 Stock ↗

June 30, 2026

It could prove to be a case of better later than never for the healthcare giant.

Via The Motley Fool

Topics Earnings

Big Pharma Has a Case of Merger Mania ↗

June 30, 2026

Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.

Via The Motley Fool

Topics Intellectual Property

Nike Just Hit an 11-Year Low. Will Its Turnaround Finally Start on Wednesday? ↗

June 30, 2026

Nike is set to report earnings on June 30. Here's what to expect.

Via The Motley Fool

Topics World Trade

3 No-Brainer Dividend Stocks to Buy Right Now ↗

June 29, 2026

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Via The Motley Fool

Topics Intellectual Property

3 Monster Stocks to Buy Right Now With Dividend Yields of 5% or More ↗

June 29, 2026

Why settle for puny yields when you can buy these monster dividend stocks?

Via The Motley Fool

Topics ETFs Energy

A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock? ↗

June 28, 2026

Things are going from bad to worse for the pharmaceutical giant.

Via The Motley Fool

Topics Intellectual Property

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now ↗

June 27, 2026

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.

Via The Motley Fool

Topics Intellectual Property

The Market Just Pulled Back Again. These 3 Blue Chips Are the Ones to Buy. ↗

June 27, 2026

Take advantage of short-term weakness by stepping into the right long-term investments when they go on sale.

Via The Motley Fool

Topics Artificial Intelligence Credit Cards Earnings

Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends ↗

June 27, 2026

The sizable yield comes with a concerning footnote. Just look at the rest of the story.

Via The Motley Fool

Topics Intellectual Property

Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next. ↗

June 27, 2026

With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.

Via The Motley Fool

Topics Artificial Intelligence Stocks

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? ↗

June 25, 2026

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

Via The Motley Fool

Topics Intellectual Property

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right? ↗

June 25, 2026

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

Via The Motley Fool

FDA Expands Pfizer's Ibrance Label For Frontline Maintenance In Advanced Breast Cancer ↗

June 25, 2026

The FDA approves Pfizer's Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance after positive Phase 3 data.

Via Benzinga

2 Large-Cap Stocks to Target This Week and 1 We Find Risky

June 25, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Via StockStory

The Highest Dividend Yields Are Often the Least Safe. Here's How to Tell the Difference. ↗

June 24, 2026

Income investors are drawn to the biggest yields, but the biggest yields frequently belong to the companies the market trusts least. A yield is simply the

Via Talk Markets

Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data ↗

June 24, 2026

Pfizer shares are trading flat in Wednesday's premarket as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape.

Via Benzinga

2 High-Yield Dividend Stocks to Buy and Hold for a Decade ↗

June 23, 2026

Don't wait until they recover to initiate positions.

Via The Motley Fool

Topics Artificial Intelligence Economy Initial Public Offering

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

June 23, 2026

Via Chartmill

Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients ↗

June 23, 2026

Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.

Via Benzinga

Pfizer Stock Edges Lower Monday: What's Going On? ↗

June 22, 2026

Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.

Via Benzinga

GEA Group Aktiengesellschaft Targets EUR 7B Revenue, Higher Margins by 2030 ↗

June 22, 2026

GEA Group Aktiengesellschaft (ETR:G1A) outlined its 2030 growth and profitability targets during an Industrial Technology Conference presentation, with Investor Relations Manager Eduard Biller saying...

Via MarketBeat

Topics Supply Chain

Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead ↗

June 22, 2026

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.

Via The Motley Fool

Topics Artificial Intelligence Earnings Intellectual Property

GLP-1 Receptor Agonist Market Revenue Analysis Across Key Regions ↗

June 22, 2026

The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion

Via Talk Markets

2 Reasons to Like ZTS and 1 to Stay Skeptical

June 22, 2026

Zoetis has gotten torched over the last six months - since December 2025, its stock price has dropped 36.6% to $78.46 per share. This was partly driven by it...

Via StockStory

Could Pfizer Stock Be Your Ticket to Generational Wealth? ↗

June 21, 2026

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.